A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the united states

Andrew Tinsley, Steven Naymagon, Arvind J. Trindade, David B. Sachar, Bruce E. Sands, Thomas A. Ullman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) patients are at an increased risk of thrombosis, particularly when hospitalized. Several clinical practice guidelines now recommend pharmacologic prophylaxis for hospitalized ulcerative colitis and Crohn’s disease patients. It is unclear to what extent gastroenterologists are aware of these recommendations and whether they are administering pharmacologic venous thromboembolism (VTE) prophylaxis appropriately. Our aim was to explore current practice of VTE prophylaxis in hospitalized IBD patients in the United States. A survey was mailed electronically to gastroenterologists whose electronic mail address was listed in the American College of Gastroenterology (ACG) database. This survey included clinical vignettes outlining scenarios for consideration of VTE prophylaxis. A total of 6227 surveys were sent to gastroenterologists nationwide, and 591 physicians chose to participate (response rate 9.5%). Respondents (80.6%) believed that hospitalized IBD patients have a higher risk of VTE than other inpatients. A total of 29.1% were unaware of any recommendations addressing pharmacologic prophylaxis included in ACG IBD guidelines and 34.6% would give pharmacologic VTE prophylaxis to a hospitalized patient with severe ulcerative colitis. Heparin VTE prophylaxis use was associated with gastroenterologists who indicated that their practices comprised more than 50% of patients with IBD (P=0.0001), being a physician at an academic hospital (P=0.0001) and providers having less than 5 years practice experience (P=0.003). Despite reasonable awareness of the increased risk of thrombosis in hospitalized IBD patients, many US gastroenterologists may not follow clinical practice guidelines and use pharmacologic VTE prophylaxis.

Original languageEnglish (US)
Pages (from-to)e1-e6
JournalJournal of Clinical Gastroenterology
Volume47
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Venous Thromboembolism
Inflammatory Bowel Diseases
Ulcerative Colitis
Practice Guidelines
Thrombosis
Physicians
Gastroenterology
Surveys and Questionnaires
Crohn Disease
Heparin
Inpatients
Gastroenterologists
Databases
Guidelines

Keywords

  • Ulcerative colitis
  • Venous thromboembolism
  • VTE prophylaxis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the united states. / Tinsley, Andrew; Naymagon, Steven; Trindade, Arvind J.; Sachar, David B.; Sands, Bruce E.; Ullman, Thomas A.

In: Journal of Clinical Gastroenterology, Vol. 47, No. 1, 01.01.2013, p. e1-e6.

Research output: Contribution to journalArticle

Tinsley, Andrew ; Naymagon, Steven ; Trindade, Arvind J. ; Sachar, David B. ; Sands, Bruce E. ; Ullman, Thomas A. / A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the united states. In: Journal of Clinical Gastroenterology. 2013 ; Vol. 47, No. 1. pp. e1-e6.
@article{b56fb4d33ced4cd6967633802e245f1c,
title = "A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the united states",
abstract = "Inflammatory bowel disease (IBD) patients are at an increased risk of thrombosis, particularly when hospitalized. Several clinical practice guidelines now recommend pharmacologic prophylaxis for hospitalized ulcerative colitis and Crohn’s disease patients. It is unclear to what extent gastroenterologists are aware of these recommendations and whether they are administering pharmacologic venous thromboembolism (VTE) prophylaxis appropriately. Our aim was to explore current practice of VTE prophylaxis in hospitalized IBD patients in the United States. A survey was mailed electronically to gastroenterologists whose electronic mail address was listed in the American College of Gastroenterology (ACG) database. This survey included clinical vignettes outlining scenarios for consideration of VTE prophylaxis. A total of 6227 surveys were sent to gastroenterologists nationwide, and 591 physicians chose to participate (response rate 9.5{\%}). Respondents (80.6{\%}) believed that hospitalized IBD patients have a higher risk of VTE than other inpatients. A total of 29.1{\%} were unaware of any recommendations addressing pharmacologic prophylaxis included in ACG IBD guidelines and 34.6{\%} would give pharmacologic VTE prophylaxis to a hospitalized patient with severe ulcerative colitis. Heparin VTE prophylaxis use was associated with gastroenterologists who indicated that their practices comprised more than 50{\%} of patients with IBD (P=0.0001), being a physician at an academic hospital (P=0.0001) and providers having less than 5 years practice experience (P=0.003). Despite reasonable awareness of the increased risk of thrombosis in hospitalized IBD patients, many US gastroenterologists may not follow clinical practice guidelines and use pharmacologic VTE prophylaxis.",
keywords = "Ulcerative colitis, Venous thromboembolism, VTE prophylaxis",
author = "Andrew Tinsley and Steven Naymagon and Trindade, {Arvind J.} and Sachar, {David B.} and Sands, {Bruce E.} and Ullman, {Thomas A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/MCG.0b013e31824c0dea",
language = "English (US)",
volume = "47",
pages = "e1--e6",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the united states

AU - Tinsley, Andrew

AU - Naymagon, Steven

AU - Trindade, Arvind J.

AU - Sachar, David B.

AU - Sands, Bruce E.

AU - Ullman, Thomas A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Inflammatory bowel disease (IBD) patients are at an increased risk of thrombosis, particularly when hospitalized. Several clinical practice guidelines now recommend pharmacologic prophylaxis for hospitalized ulcerative colitis and Crohn’s disease patients. It is unclear to what extent gastroenterologists are aware of these recommendations and whether they are administering pharmacologic venous thromboembolism (VTE) prophylaxis appropriately. Our aim was to explore current practice of VTE prophylaxis in hospitalized IBD patients in the United States. A survey was mailed electronically to gastroenterologists whose electronic mail address was listed in the American College of Gastroenterology (ACG) database. This survey included clinical vignettes outlining scenarios for consideration of VTE prophylaxis. A total of 6227 surveys were sent to gastroenterologists nationwide, and 591 physicians chose to participate (response rate 9.5%). Respondents (80.6%) believed that hospitalized IBD patients have a higher risk of VTE than other inpatients. A total of 29.1% were unaware of any recommendations addressing pharmacologic prophylaxis included in ACG IBD guidelines and 34.6% would give pharmacologic VTE prophylaxis to a hospitalized patient with severe ulcerative colitis. Heparin VTE prophylaxis use was associated with gastroenterologists who indicated that their practices comprised more than 50% of patients with IBD (P=0.0001), being a physician at an academic hospital (P=0.0001) and providers having less than 5 years practice experience (P=0.003). Despite reasonable awareness of the increased risk of thrombosis in hospitalized IBD patients, many US gastroenterologists may not follow clinical practice guidelines and use pharmacologic VTE prophylaxis.

AB - Inflammatory bowel disease (IBD) patients are at an increased risk of thrombosis, particularly when hospitalized. Several clinical practice guidelines now recommend pharmacologic prophylaxis for hospitalized ulcerative colitis and Crohn’s disease patients. It is unclear to what extent gastroenterologists are aware of these recommendations and whether they are administering pharmacologic venous thromboembolism (VTE) prophylaxis appropriately. Our aim was to explore current practice of VTE prophylaxis in hospitalized IBD patients in the United States. A survey was mailed electronically to gastroenterologists whose electronic mail address was listed in the American College of Gastroenterology (ACG) database. This survey included clinical vignettes outlining scenarios for consideration of VTE prophylaxis. A total of 6227 surveys were sent to gastroenterologists nationwide, and 591 physicians chose to participate (response rate 9.5%). Respondents (80.6%) believed that hospitalized IBD patients have a higher risk of VTE than other inpatients. A total of 29.1% were unaware of any recommendations addressing pharmacologic prophylaxis included in ACG IBD guidelines and 34.6% would give pharmacologic VTE prophylaxis to a hospitalized patient with severe ulcerative colitis. Heparin VTE prophylaxis use was associated with gastroenterologists who indicated that their practices comprised more than 50% of patients with IBD (P=0.0001), being a physician at an academic hospital (P=0.0001) and providers having less than 5 years practice experience (P=0.003). Despite reasonable awareness of the increased risk of thrombosis in hospitalized IBD patients, many US gastroenterologists may not follow clinical practice guidelines and use pharmacologic VTE prophylaxis.

KW - Ulcerative colitis

KW - Venous thromboembolism

KW - VTE prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84871623670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871623670&partnerID=8YFLogxK

U2 - 10.1097/MCG.0b013e31824c0dea

DO - 10.1097/MCG.0b013e31824c0dea

M3 - Article

VL - 47

SP - e1-e6

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 1

ER -